Xuan Zhou

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 8

Top Topics

Immune Response

Tyrosine Kinase

Top Venues

Current oncology reports

British journal of cancer

Nature communications

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Yatian Li, Zhenyue Gao, Yuhong Wang, Bo Pang, Binbin Zhang, Ruxin Hu, Yuqing Wang, Chao Liu, Xuebin Zhang, Jingxuan Yang, Mei Mei, Yong-Zhi Wang, Xuan Zhou, Min Li, Yu Ren
Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma. Nature communications 14 (1) (2023)
Lin Dong, Yu Wang, Xiaofeng Yao, Yu Ren, Xuan Zhou
Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not? Current oncology reports 25 (2) (2022)
Lin Dong, Yu Wang, Xiaofeng Yao, Yu Ren, Xuan Zhou
Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not? Current oncology reports 25 (2) (2022)
Yuqing Wang, Jiang Du, Zhenyue Gao, Haoyang Sun, Mei Mei, Yu Wang, Yu Ren, Xuan Zhou
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. British journal of cancer (2022)
Lin Dong, Yu Wang, Xiaofeng Yao, Yu Ren, Xuan Zhou
Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not? Current oncology reports (2022)
Lin Dong, Yu Wang, Xiaofeng Yao, Yu Ren, Xuan Zhou
Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not? Current oncology reports 25 (2) (2022)
Yiqi Xu, Zhenyue Gao, Ruxin Hu, Yuqing Wang, Yuhong Wang, Zheng Su, Xiaoyue Zhang, Jingxuan Yang, Mei Mei, Yu Ren, Min Li, Xuan Zhou
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. Journal for immunotherapy of cancer 9 (10) (2022)
Lin Dong, Yu Wang, Xiaofeng Yao, Yu Ren, Xuan Zhou
Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not? Current oncology reports 25 (2) (2022)